Covid 19 cases surge in India; two unique symptoms of new variant JN.1 which are different from previous other strains
Tired of too many ads? go ad free now
Closer home, the country has been seeing a rise in variant NB.1.8.1 and LF.7 variants, detected recently in different parts of the country. While the disease is still endemic, and (for now) poses no immediate threat according to the government, what is this new variant, and what makes it different from the rest? While it shares many features with previous Omicron sub variants, there are two notable symptoms that stand out as different in JN.1 infections.
Let's dig deeper...
What is the JN.1 COVID-19 Variant?
JN.1 is actually a subvariant of the Omicron, evolving from the BA.2.86 variant, also known as Pirola. It was first identified in Luxembourg in 2023 and since has gradually spread to other parts of the world, and now India. JN.1 is said to be more transmissible than previous variants due to specific mutations in its spike protein, which helps it binds to humans easily.
However, as of now, there is no data to prove that it causes any serious illness.
Common Symptoms of JN.1
Most symptoms of JN.1 are similar to other Omicron variants and include:
Fever or chills
Dry cough
Sore throat
Fatigue
Headache
Runny or blocked nose
Muscle aches
Shortness of breath (in severe cases)
These symptoms usually appear 2 to 14 days after exposure and are often mild, with patients recovering quickly at home only.
Tired of too many ads? go ad free now
The two different symptoms
While many symptoms overlap with previous COVID-19 strains, two symptoms have been reported more frequently or distinctly in JN.1 infections:
Persistent Low-Grade fever
Unlike earlier variants where high fever with sweating and chills was common, JN.1 infections often cause a persistent low-grade fever, typically between 37.6°C and 38.1°C.(99.6-100.5°F) This fever does not show regular symptoms like rapid breathing, or warm to the touch.
Instead, it alters the body's temperature regulation, known as hyperthermia. People may feel slightly warm for several days without the intense fever spikes seen in previous COVID waves.
This symptom can be easily overlooked or mistaken for mild tiredness or other minor illnesses. The continuous mild fever signals the body is fighting the virus but in a less aggressive way than before. Recognizing this can prompt early testing and isolation to prevent spread to others.
Gastrointestinal issues
Another symptom that sets JN.1 apart is the increased frequency of digestive issues such as nausea, loss of appetite, stomach discomfort, and diarrhea. While gastrointestinal symptoms were present in earlier COVID-19 variants as well, they were less common and often mild. With JN.1, these symptoms seem to be more prominent and affect a larger number of patients.
According to doctors, this change may be due to the virus's altered behavior in the body or its interaction with the gut's immune system.
Digestive symptoms can sometimes appear alongside or even before respiratory symptoms like cough and sore throat, which is different from earlier strains. On the other hand major respiratory issues have not been reported in this strain.
Why the difference
The unique symptoms of JN.1 arise from its genetic mutations, especially in the spike protein. These mutations make the virus more contagious by its quick ability to bind to human cells.
However, they do not seem to increase the severity of illness. Instead, the virus causes a different pattern of symptoms, reflecting subtle changes in how it affects the body.
What Should You Do If You Experience These Symptoms?
If you notice a mild, continuous fever without sweating or chills, or if you develop nausea, loss of appetite, or stomach discomfort along with respiratory symptoms, it is wise to:
Get tested for COVID-19 to confirm infection, especially if you have been exposed to someone with the virus or have recently traveled.
Self-isolate to avoid spreading the virus to others.
Stay hydrated and rest well.
Monitor symptoms carefully, and seek medical help if you experience breathing difficulties.
Keep your vaccinations up to date, including boosters, as they still remain your best bet against severe illness.
Where Are These Variants Found in India?
NB.1.8.1: First detected in Tamil Nadu in April 2025.
LF.7: Four cases confirmed in Gujarat in May 2025.
Other states reporting active COVID-19 cases linked to these or other variants include Kerala, Maharashtra, Karnataka, Delhi, and several northeastern states. Kerala currently has the highest number of cases, followed by Tamil Nadu and Maharashtra. The rise, while noticeable, is not yet worrisome.
Impact on Vaccines and Treatments
Current vaccines and treatments remain effective against these new variants.
Health authorities emphasize the importance of vaccination and boosters to maintain protection. There is no indication that NB.1.8.1 or LF.7 significantly evade immunity from vaccines or past infections, unlike some earlier variants that partially escaped immune responses.
Stay safe, but don't panic
Despite its unique symptoms, JN.1 is not more dangerous in terms of severity but spreads more easily. Therefore, preventive steps remain key to controlling its impact:
Wearing masks in crowded or enclosed spaces.
Practicing good hand hygiene.
Avoiding close contact with sick individuals.
Following public health advice on vaccination and boosters.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Study finds COVID-19 may have aged blood vessels by 5 years, especially among women
New Delhi: A COVID-19 infection could age one's blood vessels by about five years, especially among women, according to a new study. The effect was found to be stronger among women who experienced persistent symptoms after recovering from COVID-19 -- collectively termed 'long Covid' -- such as shortness of breath and fatigue. "Since the pandemic, we have learned that many people who have had (COVID-19) are left with symptoms that can last for months or even years. However, we are still learning what's happening in the body to create these symptoms," lead researcher Rosa Maria Bruno from Universite Paris Cite, France, said. The study, published in the European Heart Journal, looked at around 2,400 people -- about half were women -- from across 16 countries, including Australia, Brazil and those in Europe. While blood vessels are known to become stiffer with age, a COVID-19 infection can accelerate the process and can heighten the risk of developing cardiovascular disease, including stroke and heart attack, the researchers said. The participants' vascular (blood vessel) age was measured using a device that looks at how quickly a wave of blood pressure travels between the carotid artery (in the neck) and femoral arteries (in the legs) -- called 'carotid-femoral pulse wave velocity'. A higher value indicates more stiffness and ageing of blood vessels. Measurements were taken six months after a COVID-19 infection and again after 12 months. An increase in pulse wave velocity of around 0.5 metres per second is clinically relevant and roughly amounts to ageing by five years, with a three per cent increased risk of cardiovascular disease, in a 60-year-old woman, the researchers said. The study found that, on average, pulse wave velocity among women who had a mild infection was increased by 0.55 metres per second, by 0.60 metres per second in those hospitalised and by over one metre per second for women treated in intensive care. "(Pulse wave velocity) differences were significant in women, but not in men. Among COVID-19 positive women, persistent symptoms were associated with higher (pulse wave velocity)," the authors wrote. "A stable or improved (pulse wave velocity) after 12 months was found in COVID-positive groups, whereas a progression was observed in the COVID-negative group," they wrote. Explaining how COVID-19 impacts blood vessels, Bruno said that the disease-causing virus "acts on specific receptors in the body, called the angiotensin-converting enzyme 2 receptors, that are present on the lining of the blood vessels." "The virus uses these receptors to enter and infect cells. This may result in vascular dysfunction and accelerated vascular ageing. Our body's inflammation and immune responses, which defend against infections, may also be involved," the lead researcher said. Further, compared to men, women are known to produce a more rapid and robust immune response which can protect from infection but can also inflict damage on blood vessels after initial infection, Bruno said. In a related editorial, published in the European Heart Journal, researchers from Harvard Medical School in the US wrote, "Although the acute threat of the COVID-19 (coronavirus disease 2019) pandemic has waned, a new challenge emerged in its aftermath: post-acute COVID-19 syndrome." The study highlights that "COVID-19's vascular legacy is real, measurable, and with a plausible likelihood of sex-specific findings," they wrote. "COVID-19 has aged our arteries, especially for female adults. The question is whether we can find modifiable targets to prevent this in future surges of infection, and mitigate adverse outcomes in those afflicted with COVID-19-induced vascular ageing," the authors said.>
India Today
5 hours ago
- India Today
Should you take weight loss drugs? The truth behind weight loss pills
This episode of Five Live focusses on obesity, a major health concern in India, where approximately 40.3% of adults are clinically obese. The discussion highlights the limitations of Body Mass Index (BMI) as a sole parameter for defining fatness, suggesting alternative methods like waist-to-hip ratio and body fat percentage. It also differentiates between visible fat and visceral fat, emphasising the dangers of the latter. The segment explores the emergence of anti-obesity drugs, including GLP-1, Banjaro, and Vigovi, as a significant pharmaceutical advancement. A critical point raised is the challenge of ensuring these drugs are used appropriately. It is stated that "The key here is that this is not a drug that can be self-prescribed. The key here is you need to know when to start, how much to have and importantly when to stop."
&w=3840&q=100)
Business Standard
5 hours ago
- Business Standard
Glenmark, Alembic Pharma, Sun Pharma recall drugs in US, says USFDA
Drug makers Glenmark, Alembic Pharmaceuticals and Sun Pharma are recalling products in the US due to manufacturing issues, according to the US health regulator. Mumbai-based Glenmark is recalling two products in the market, the US Food and Drug Administration (USFDA) said in its latest Enforcement Report. Glenmark Pharmaceuticals Inc, USA, a subsidiary of the company, is recalling Carvedilol tablets, used to treat heart failure, hypertension, and heart attack, in multiple strengths. The New Jersey-based firm is recalling 55,560 units of the affected lot due to "presence of a nitrosamine, N-Nitroso Carvedilol impurity above the current acceptable intake level," the USFDA stated. The company is also recalling 17,496 bottles of Carvedilol tablets as "results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm," it added. Glenmark initiated the Class II recall in August this year. USFDA said the company is also recalling 22,656 bottles of Theophylline extended-release tablets (400 mg) for failed dissolution specifications. Alembic Pharmaceuticals is recalling 9,492 bottles of Doxepin Hydrochloride capsules, used in the treatment of insomnia, the US health regulator stated. The Class II recall is due to the "Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit," it said. The company initiated the recall on July 25 this year. New Jersey-based Sun Pharmaceutical Industries Inc is recalling 11,328 bottles of Spironolactone Tablets, used to treat high blood pressure, due to "Presence of foreign substance: identified as aluminum," the regulator said. The company commenced the Class II recall on August 5. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.
